Novo Nordisk filed a patent lawsuit against Hims & Hers over compounded Wegovy. The FDA confirmed no semaglutide shortage, reducing concerns about drug access. Hims launched a $49 version of Wegovy, prompting Novo’s lawsuit seeking significant damages. Hims argues against Novo’s lawsuit, defending compounding practices improving patient care. (50 words)

Telehealth company Hims expects $2.3 billion in revenue by 2025 and aims for $6.5 billion by 2030. Novo’s lawsuit marks a shift in pharmaceutical companies suing compounding pharmacies. U.S. regulations allow compounding during drug shortages. Novo previously focused on safety and trademark lawsuits, avoiding patent litigation during the semaglutide shortage. (50 words)

Novo escalated its legal fight against Hims over compounded Wegovy. Experts anticipate a battle over patent validity. Novo may seek an injunction to block Hims’ sales. The FDA could restrict GLP-1 ingredients in compounded drugs. Novo’s lawsuit against Hims is a warning to other companies infringing patents. (50 words)

Read more at Yahoo Finance: Novo Nordisk opens new front with patent suit over Hims’ Wegovy copies